Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Age-Related Macular Degeneration (AMD): Update Bulletin [September 2016]

Product Code:
596200615
Publication Date:
September 2016
Format:
PDF
Price:
€1010

Gain new KOL insights on the latest events happening in AMD: Australian biotech Opthea’s July 2016 release of topline data from its ongoing first-in-human clinical trial of OPT-302, a novel VEGF-C/D 'Trap' therapy for wet age-related macular degeneration (wet AMD); the July 2016 announcement of Adverum Biotech intent to move forward with development of its anti-VEGF wet AMD gene therapy candidates after promising pre-clinical data in recently completed non-human primate studies and Ophthotech’s  completion of patient recruitment in its Phase III trial of Fovista (pegpleranib), an anti-platelet derived growth factor subunit B (PDGF-B) aptamer, in combination with Eylea (aflibercept) or Avastin (bevacizumab), for the treatment of wet AMD.

Highlights from this event update bulletin

  • What are KOL’s reactions to Opthea OPT-302, the novel VEGF-C/D 'Trap' therapy, for wet AMD?
  • Do experts have any concerns about inhibition of VEGF-C/D pathway?
  • How will OPT-302 fit into the wet AMD treatment algorithm?
  • How do KOLs view Adverum Biotech’s anti-VEGF wet AMD gene therapy candidates?
  • What key challenges do experts think need to be overcome by gene therapy candidates for eye diseases? 
  • Will a wet AMD gene therapy reach the market in next five year?
  • What do KOLs think of Ophthotech’s Phase III trials for Fovista (pegpleranib)?
  • How is Fovista likely to be used in AMD patients and will it impact existing therapies?



customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved